Hans Prenen

机构：University of Antwerp, Antwerp University Hospital · ORCID：0000-0001-8802-7352

发表论文 478 篇 · 总被引 15461 次 · h-index 55

代表论文

IL-15 boosts Mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting (2026 · Molecular Therapy Oncology)
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318 (2026 · Journal for ImmunoTherapy of Cancer)
Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study (2026 · JCO Precision Oncology)
Supplementary Figure S8 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer (2026)
Supplementary Figure S9 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer (2026)
Supplementary Figure S14 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer (2026)